Pfizer Inc. (PFE) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription dru...
Pfizer Inc.'s revenue decreased 1.6% year over year, from $63.63B to $62.58B.
Net income decreased 3.2% over the same period, from $8.03B to $7.77B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 18% in total.
Total debt remained relatively stable at $65.15B.
The debt-to-equity ratio stands at 0.75, indicating a moderate leverage profile.
Operating cash flow declined 8.2% to $11.70B.
Pfizer Inc. maintains a healthy net profit margin of 12.4%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $17.70B+33.3% | $4.46B | $12.44B | $354.0M | $6.71B | $219.00B | $67.70B | $92.29B |
| Q4 FY2024 | $17.76B+0.3% | $410.0M | $11.85B | $-10.0M | $6.72B | $213.00B | $63.95B | $88.20B |
| Q1 FY2025 | $13.71B-22.8% | $2.97B | $10.87B | $2.79B | $2.33B | $208.00B | $62.11B | $90.34B |
| Q2 FY2025 | $14.65B+6.8% | $2.91B | $10.87B | $3.04B | $-582.0M | $206.00B | $61.80B | $88.69B |
| Q3 FY2025 | $16.66B+13.7% | $3.54B | $12.48B | $3.33B | $4.60B | $209.00B | $61.71B | $92.80B |
| Q4 FY2025 | $17.56B+5.4% | $-1.65B | $12.29B | $10.00B | $5.35B | $208.00B | $65.15B | $86.48B |
| Q1 FY2026 | $14.45B-17.7% | $2.69B | $10.90B | $3.17B | $2.62B | $207.62B | $64.73B | $90.40B |
| Q2 FY2026 | $15.03B+4.0% | $-247.0M | $10.94B | $5.59B | $835.0M | $201.13B | $63.48B | $85.49B |
Balance Sheet Summary (Q2 FY2026)
Pfizer Inc. (PFE) Financial Statements & Revenue History
Pfizer Inc. (PFE) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry trading at $29.58 with a market capitalization of $169. This page provides 42 historical financial statements for Pfizer Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Pfizer Inc. reported revenue of $62.6 billion, a 1.6% decline from the prior year. The net profit margin of 12.4% indicates moderate profitability. The debt-to-equity ratio of 0.75 reflects moderate leverage.
PFE Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Pfizer Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether PFE is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track PFE's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Pfizer Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of PFE's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use PFE Financial Data
Investors use Pfizer Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare PFE's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how PFE's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View PFE's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Pfizer Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.PFE trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.